drugset / Trial / NCT02193347
IDH1 Peptide Vaccine for Recurrent Grade II Glioma
NaSingle-groupOpen-labelTreatment
Summary
Potential subjects with progressive Grade II primary brain tumor that have IDH1 positive testing from the primary tumor (initial diagnosis) will be offered this treatment study in order to test the safety of the PEPIDH1M vaccine in combination with standard chemotherapy (temozolomide).
Timeline
- Start
- 2016-01-28
- Primary completion
- 2020-02-03
- Completion
- 2020-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEPIDH1M | Peptide | 500 ug | Intravenous |
| Background | TENIVAC | Vaccine | 0.5 ml | Intramuscular |
| Background | TENIVAC | Vaccine | 1 unknown | Intramuscular |
| Background | Temozolomide | Small molecule | 50 mg/m2 | — |
| Background | Temozolomide | Small molecule | 100 mg/m2 | — |